Form 4: Disc Medicine CEO Exercises Options for 10,000 Shares

Disc Medicine, Inc. CEO John D. Quisel exercised stock options to acquire 10,000 shares of common stock at $1.01 per share, effective September 9, 2025, under a pre-arranged 10b5-1 plan.

Summary

• John D. Quisel, Chief Executive Officer and Director of Disc Medicine, Inc. (IRON), will acquire 10,000 shares of common stock.
• The acquisition is a result of exercising stock options at a price of $1.01 per share.
• This transaction is scheduled for September 9, 2025, and is being made pursuant to a Rule 10b5-1(c) plan.
• Following this transaction, Quisel will directly own 171,828 shares of common stock.
• He will also retain 198,420 derivative securities (stock options) after the transaction.
• The exercised options were fully vested and exercisable as of the date of the filing.

Sentiment

Score: 7

Explanation: The exercise of options by a CEO to increase direct share ownership is generally viewed positively as it aligns management's interests with shareholders. The transaction being under a 10b5-1 plan adds transparency and reduces concerns about opportunistic timing. The future date of the transaction is a neutral factor as it's pre-scheduled.

Positives

• CEO John D. Quisel is increasing his direct ownership in Disc Medicine, Inc. by 10,000 shares, which can be seen as a vote of confidence in the company's future prospects.
• The transaction is pre-scheduled under a Rule 10b5-1 plan, indicating a planned and systematic approach to insider trading, which reduces concerns about opportunistic timing.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the scheduled transaction date.

Management Comments

• The shares underlying this option are fully vested and exercisable as of the date hereof.

Industry Context

This Form 4 filing details an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry context or competitive analysis.

Comparison to Industry Standards

• This filing is a standard insider transaction disclosure. There are no specific comparable companies, projects, or results mentioned to assess against global benchmarks.

Stakeholder Impact

• Shareholders: Increased alignment of CEO's interests with shareholders due to higher direct ownership.

Next Steps

• The transaction of 10,000 shares is scheduled to occur on September 9, 2025.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the CEO is exercising pre-existing stock options under a 10b5-1 plan. While increasing insider ownership is generally a positive signal, this specific transaction is pre-scheduled and does not indicate new discretionary buying or selling activity that would warrant a change in investment recommendation. It's a neutral event for immediate investment decisions.

Keywords

Disc Medicine, IRON, John D. Quisel, CEO, Director, Stock Option Exercise, Insider Trading, Form 4, 10b5-1 Plan, Equity Acquisition